Personalized Therapeutics: Clinical Reality and Future Challenges

Personalized Therapeutics: Clinical Reality and Future Challenges

Thursday, February 15 | 9 a.m. ET | Virtual

Speaker: George P. Patrinos

Dr. Patrinos is a professor of pharmacogenomics and pharmaceutical biotechnology in the University of Patras’ (Greece) Department of Pharmacy, and holds adjunct professorships at Erasmus MC, Faculty of Medicine, Rotterdam (the Netherlands) and the United Arab Emirates University, College of Medicine, Department of Genetics and Genomics, Al-Ain (UAE). He also served for 12.5 years as full member and Greece’s National Representative in the CHMP Pharmacogenomics Working Party of the European Medicines Agency (EMA) and as Chair of the Global Genomic Medicine Collaborative (G2MC) since 2018.

About the Talk: This talk will provide a summary of the PREPARE and Em-HEART clinical studies in psychiatry and cardiology, and ethical and regulatory challenges in the field of pharmacogenomics.

To learn more and register, visit the GGMC Educational Webinar Series webpage.

Please note: Registration is required.

GGMC Educational Webinar on February 15, 2024 featuring Dr. George P. Patrinos.

Pharmacogenomics in treatment of depression and psychosis: an update

Posted on by Alexis

Marin Jukic, Filip Milosavljević, Espen Molden, Magnus Ingelman-Sundberg

Abstract

Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.

Keywords: ADME genes; drug metabolism; personalized medicine; pharmacogenomics; psychiatric genetics